| Autor: |
Sperotto, Alessandra, Lupo Stanghellini, Maria Teresa, Peccatori, Jacopo, De Marchi, Roberta, Piemontese, Simona, Ciotti, Giulia, Basso, Marco, Pierdomenico, Elisabetta, Fiore, Paolo, Ciceri, Fabio, Gottardi, Michele |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology; 2024, p1-11, 11p |
| Abstrakt: |
Therapy-related myeloid neoplasms (t-MNs), which develop after cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, account for 7%-8% of acute myeloid leukemia (AML). Worse outcomes and consequently shortened survival are associated with t-MNs as compared with de novo AML. Therapy-related MNs are being reported with increasing frequency in successfully treated acute promyelocytic leukemia (APL), in particular, before the introduction of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO). Considering the high curability of APL, t-MNs represent one of the prognosis-limiting factors in this setting of leukemia. We report our experience with a patient who developed t-AML 15 years after treatment for APL. Treatment included three cycles of chemotherapy with CPX-351 (Vyxeos, Jazz Pharmaceuticals) followed, as in remission, by an allogeneic hematopoietic stem cell transplant. A review of available literature was also included. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
